Neurocrine Biosciences Reports Q3 Earnings Beat and Raises Ingrezza Sales Guidance
Neurocrine Biosciences (NBIX) reported third-quarter financial results that exceeded market expectations, posting a Non-GAAP EPS of $3.29, which beat estimates by $0.54. The company's revenue reached $1.12 billion, representing a significant 40.9% increase year-over-year and surpassing analyst projections by $80 million. Driven by strong product performance, the company raised its 2026 net sales guidance for INGREZZA (valbenazine) to a range of $2.9 billion to $2.925 billion. Despite these robust financial results, the stock has faced recent pressure due to resurfacing safety concerns related to Vykat XR.
Tickers: $NBIX
Topics: earnings beat guidance raise pharmaceuticals revenue growth
Read the full article at Seeking Alpha
Part of the story Palantir Technologies Shares Decline Despite Record Q3 Revenue and Raised Guidance (16 articles)